{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-257382","form_type":"8-K","ticker":"PHAT","cik":"0001783183","company_name":"Phathom Pharmaceuticals, Inc.","filed_at":"2025-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.440620+00:00","generated_at":"2026-05-17T01:23:51.172566+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Phathom Q3 revenue $49.5M, up 25% QoQ; net loss $30M; FY guidance raised to $170-175M","bullets":["Net revenue of $49.5M in Q3 2025, up 25% from Q2 and from $16.4M in Q3 2024.","Net loss narrowed to $30.0M from $85.6M in Q3 2024; non-GAAP adjusted net loss $11.2M.","Full-year 2025 revenue guidance raised to $170-175M; expects operating profitability in 2026.","Over 790,000 cumulative VOQUEZNA prescriptions filled; Q3 filled prescriptions up 28% QoQ.","Appointed Sanjeev Narula as CFO/Chief Business Officer and Nancy Phelan as SVP Marketing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-257382","json":"https://secwatch.observer/filing/0001193125-25-257382.json","markdown":"https://secwatch.observer/filing/0001193125-25-257382.md","text":"https://secwatch.observer/filing/0001193125-25-257382.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783183/000119312525257382/0001193125-25-257382-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783183/000119312525257382/d68071d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:23:51.172566+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}